Latest Ratios: P/E Ratio N/A · EV/EBITDA N/A · ROE -58.6%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $40M | — | $14M | $23.4B | — | — |
| Enterprise Value | $32M | — | $8M | $23.4B | — | — |
| P/E Ratio → | — | — | 14.16 | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | — | — | 2.13 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | 8.01 | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -58.6% | -58.6% | 15.1% | -43.8% | 2.9% | 2.7% |
| ROA | -55.8% | -55.8% | 24.0% | -39.3% | 2.7% | 2.5% |
| ROIC | -92.8% | -92.8% | — | -1.7% | -1.2% | — |
| ROCE | -52.7% | -52.7% | -54.5% | -2.4% | -1.5% | -0.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.00 | — |
| Debt / EBITDA | — | — | — | — | 0.06 | — |
| Net Debt / Equity | — | -0.44 | -0.91 | — | 0.00 | -0.00 |
| Net Debt / EBITDA | — | — | — | — | 0.06 | -0.22 |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -727.46 | -727.46 | 110.15 | -965.34 | — | — |
Net cash position: cash ($7M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 14.62 | 14.62 | 11.04 | 0.09 | 0.08 | 5.59 |
| Quick Ratio | 14.62 | 14.62 | 11.04 | 0.09 | 0.08 | 5.86 |
| Cash Ratio | 11.95 | 11.95 | 10.32 | 0.06 | 0.00 | 3.03 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 7.1% | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | — | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $0 | $568018 | $7M | $33M | $33M |
Clinical trial funding exhaustion
As reported in financial statements, PBM's ROIC plummeted to -40.5% in 2023Q2, illustrating a severe inability to generate returns on invested capital while the firm remains in a pre-revenue clinical development phase that consumes rather than compounds shareholder resources.
The persistent negative ROIC trend suggests that the company's current capital allocation is entirely focused on R&D burn rather than productive asset utilization. Investors should monitor whether the transition to clinical milestones can eventually stabilize these returns, though current figures indicate significant value destruction.
Based on recent SEC filings, the company's current ratio deteriorated to a precarious 0.09 as of 2023Q3, signaling that liquid assets are insufficient to cover immediate obligations and leaving the firm with virtually no margin for operational error or unexpected clinical delays.
This liquidity profile suggests that the company is operating with extreme financial fragility, relying heavily on external capital injections to maintain basic functionality. The lack of a meaningful quick ratio buffer warrants further investigation into the firm's ability to sustain its current trial schedule without immediate dilution.
According to historical balance sheet data, the company's debt-to-equity profile has become increasingly distorted, with negative equity of $11.0K as of 2023Q3, highlighting a structural reliance on external financing to offset the cumulative impact of persistent operational losses.
While absolute debt levels remain low, the presence of negative equity suggests that the company has effectively exhausted its internal capital base. This leverage dynamic implies that any future financing will likely come at a significant cost to existing shareholders through further equity dilution.
As indicated by the absence of revenue, traditional valuation ratios like P/E or EV/EBITDA are fundamentally misapplied to PBM, as they obscure the reality that the firm's value is derived entirely from clinical trial optionality rather than current earnings power.
Analysts should instead focus on the 'cash runway' or 'time-to-exhaustion' metrics, which better capture the firm's operational reality as a clinical-stage entity. Applying standard valuation multiples to this business model risks creating a false sense of comparability with mature healthcare firms that possess established revenue streams.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PBM stock.
Psyence Biomedical Ltd.'s return on equity (ROE) is -58.6%. The historical average is -16.3%.
Based on historical data, Psyence Biomedical Ltd. is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.